Given the complexity and cost of the commercialisation journey, strategic alliances and partnerships become a key decision for all founders. This panel will discuss the who, the why, and perhaps most crucially the decision around when to partner.
- Improving capital efficiency within the animal health market
- Factors to consider when evaluating and planning route to market
- How strategic partners will leverage data and AI to help guide start-ups and speed to commercialisation
- Drivers of successful partnerships and the realisation of value
Moderator
Panellists
Megan Grether
Head of Global Business Development and Licensing Animal Health
Boehringer Ingelheim
Jim McIntyre
Head of Global Business Development
Merck Animal Health
Justine Conway
Vice President of Business Development & External Innovation
Elanco
The past 12 months have seen rapid innovation and transformation across the Animal Health industry. Stonehaven Cozmix Group explores advancements in technology and business models shaping the sector’s future, including
- Major launches – Spotlight on new launches in Companion Animal dermatology, cardiology, and parasiticides and Farm Animal vaccines
- Generics Landscape – Evolving competition and market dynamics
- Business Activity – Notable M&A transactions and start-up funding
- Innovative Models – Emerging business approaches reshaping customer engagement and routes to commercialisation
- AI in Animal Health – Growing applications across R&D, diagnostics, and decision-making.
Matthias Hofer
Managing Partner
Stonehaven Cozmix Group
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Chad Terrell
Head of Business Development
Stonehaven Cozmix Group
Stonehaven Cozmix Group
Website: https://www.sc.group/
Stonehaven Cozmix Group (SC Group) is a global life sciences management consultancy firm that serves innovative life sciences companies at various phases of development. The company was created upon the merger of Stonehaven Consulting AG and Cozmix Inc.
Cozmix was founded in 2005 and has successfully advised life science clients in commercial resource allocation with their proprietary tools and software suite. Stonehaven Consulting was established in 2015 and has since then delivered numerous strategy projects for clients in animal health, human health, and private equity.
The merger creates an international leader in life science consulting, focused on commercial strategy and commercial resource allocation where clients can benefit from a broadened service and technology offering, addition expertise, and expanded global presence with offices in Switzerland, UK and USA.
Zoetis
Website: https://www.zoetis.com/
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees.
For more information, visit www.zoetis.com